These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

175 related items for PubMed ID: 2029165

  • 1. Genetic polymorphisms in drug metabolism--its relevance to Asian populations.
    Lee EJ.
    Ann Acad Med Singap; 1991 Jan; 20(1):56-60. PubMed ID: 2029165
    [Abstract] [Full Text] [Related]

  • 2. Molecular mechanisms of genetic polymorphisms of drug metabolism.
    Meyer UA, Zanger UM.
    Annu Rev Pharmacol Toxicol; 1997 Jan; 37():269-96. PubMed ID: 9131254
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations.
    Nakamura K, Goto F, Ray WA, McAllister CB, Jacqz E, Wilkinson GR, Branch RA.
    Clin Pharmacol Ther; 1985 Oct; 38(4):402-8. PubMed ID: 4042523
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Polymorphic drug metabolism.
    Relling MV.
    Clin Pharm; 1989 Dec; 8(12):852-63. PubMed ID: 2689060
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Genetic polymorphism of oxidative drug metabolism. Therapeutic and toxicologic implications].
    Eichelbaum M.
    Internist (Berl); 1983 Mar; 24(3):117-27. PubMed ID: 6135670
    [No Abstract] [Full Text] [Related]

  • 14. Debrisoquin and S-mephenytoin hydroxylation phenotypes and CYP2D6 genotypes in an Estonian population.
    Marandi T, Dahl ML, Kiivet RA, Rägo L, Sjöqvist F.
    Pharmacol Toxicol; 1996 May; 78(5):303-7. PubMed ID: 8737964
    [Abstract] [Full Text] [Related]

  • 15. [Heritable polymorphisms in oxidative drug metabolism].
    Kallio J.
    Duodecim; 1990 May; 106(5):408-14. PubMed ID: 1670108
    [No Abstract] [Full Text] [Related]

  • 16. Genetic polymorphism of drug metabolism in humans.
    Gross AS, Kroemer HK, Eichelbaum M.
    Adv Exp Med Biol; 1991 May; 283():627-40. PubMed ID: 2069031
    [No Abstract] [Full Text] [Related]

  • 17. Polymorphisms in drug-metabolizing enzymes: what is their clinical relevance and why do they exist?
    Nebert DW.
    Am J Hum Genet; 1997 Feb; 60(2):265-71. PubMed ID: 9012398
    [No Abstract] [Full Text] [Related]

  • 18. Genetic polymorphisms of debrisoquine and S-mephenytoin oxidation metabolism in Chinese populations: a meta-analysis.
    Xie HG, Xu ZH, Luo X, Huang SL, Zeng FD, Zhou HH.
    Pharmacogenetics; 1996 Jun; 6(3):235-8. PubMed ID: 8807662
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Debrisoquine and S-mephenytoin hydroxylation polymorphisms in a Russian population living in Estonia.
    Marandi T, Dahl ML, Rägo L, Kiivet R, Sjöqvist F.
    Eur J Clin Pharmacol; 1997 Jun; 53(3-4):257-60. PubMed ID: 9476041
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.